Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13194019 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL14929306 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL325079 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL12374613 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL11982565 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL16884139 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL12302343 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL11965635 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL24672314 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL8815319 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108424433-B | Alpha nucleoside synthesis method | 上海兆维科技发展有限公司 | 2021-04-23 | — | — | CN | claimed |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-114057815-B | Novel 6-6 bicyclic aromatic ring substituted nucleosides as PRMT5 inhibitors | 詹森药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4353732-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-0496617-B1 | Adenosine kinase inhibitors | METABASIS THERAPEUTICS INC (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5864033-A | ENZYME INHIBITORS WITH HETEROCYCLIC BASES | METABASIS THERAPEUTICS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5646128-A | TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS | GENSIA, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | ENTPD5, ENTPD1, ENTPD2 | CA2 320/4885CA1 865/4885CA9 349/4885 |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | CA2 3466/4885CA1 2420/4885CA9 2062/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | CA2 824/4885CA1 1176/4885CA9 787/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CA2 2640/4885CA1 928/4885CA9 1264/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | CA2 2640/4885CA1 928/4885CA9 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.